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Chapter 13
Mouse Model of Colitis-Associated Colorectal Cancer 
(CAC): Isolation and Characterization of Mucosal- 
Associated Lymphoid Cells
Llipsy Santiago, Marta Castro, Julián Pardo, and Maykel Arias
Abstract
Colorectal cancer (CRC) is the third most common malignancy worldwide presenting high mortality due 
to low treatment efficacy. Existing evidence indicates that inflammatory bowel disease (IBD) is associated 
with a higher risk of developing CRC. Many murine models of inflammation-related colon carcinogenesis 
(CAC) have been developed to study colon carcinogenesis and novel treatments. A commonly used model 
involves the combination of a single dose of azoxymethane (AOM), together with three cycles of the 
inflammatory agent dextran sodium sulfate (DSS) (5 days in drinking water followed by a two-week rest). 
Following this protocol, around 50% of the animals develop CRCs after 45 days and almost 100% of ani-
mals after 60 days. During CAC development, immune cells, cytokines, and other immune mediators are 
involved in both tumorigenesis and the elimination of cancer cells during immunotherapy. Thus, the study 
of mucosal immune responses (including lamina propria mononuclear cells and intraepithelial lympho-
cytes) is important to understand the role of the immune system during development and therapy in 
CRC.  Single immune cell suspensions from lamina propria and epithelium can be purified combining 
selective tissue digestion and Percoll gradient centrifugation. Isolated cells can be characterized using flow 
cytometry by analyzing surface antigens or intracellular cytokines and cytotoxic mediators or employed for 
further investigations like comparative studies of mRNA expression, cell-proliferation assay, protein analy-
sis, or even functional cytotoxicity assays. The CAC model is useful to study the involvement of immune 
cells not only during the carcinogenesis process but, in addition, during the treatment with novel immu-
notherapy protocols.
Key words Colitis-associated cancer (CAC), Azoxymethane (AOM), Lamina propria, Monocyte cells 
(LPMCs), Intraepithelial lymphocytes (IELs), Dextran sodium sulfate (DSS)
1 Introduction
Colorectal cancer (CRC) is the third most common malignancy 
worldwide. This cancer can develop spontaneously or as a late 
complication of a chronic inflammatory state. The risk of develop-
ing CRC involves many genetic and hereditary factors as well as 
environmental and lifestyle risk factors [1]. However, in all cases, 
inflammation seems to contribute to the tumorigenesis process.
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The connection between inflammation and tumorigenesis is 
well established and appears to be mediated by the activity of 
immune cells. The molecular mechanisms by which inflammation 
promotes cancer development are still being uncovered and could 
differ between colitis-associated cancer (CAC) and other forms of 
colorectal cancer (CRC) [2–5]. Recent works have elucidated the 
role of immune cells, cytokines, and other immune mediators in all 
steps of colon tumorigenesis, including initiation, promotion, pro-
gression, and metastasis [4, 6, 7]. Paradoxically, some of these 
immune mediators are also involved in protection against cancer 
during both immunosurveillance and immunotherapy.
The study of experimental colon carcinogenesis in rodents has 
a large history. Many murine models of sporadic and inflammation- 
related colon carcinogenesis have been developed to study colon 
carcinogenesis, including genetically engineered mouse models, 
chemically induced CRC models, and xenotransplants. All these 
animal models have provided important tools for investigating the 
development and pathogenesis of CRC and help us understand the 
sequential of genetic and epigenetic alterations that trigger changes 
in cell and tumor biology, which is observed in humans [8]. In 
addition, they are very useful to analyze the efficacy of novel che-
motherapy and immunotherapy treatments in colorectal cancer.
Among the chemically induced CRC models, the combination 
of a single dose of azoxymethane (AOM) with three cycles of dex-
tran sodium sulfate (DSS) has proven to shorten the latency time 
for induction of CRC in rodents. Besides, the tissue injuries quickly 
reach the aberrant crypt foci–adenoma–carcinoma sequence that 
occurs in human CRC.  The DSS/AOM model has become a 
prominent model for studying colon carcinogenesis and CRC 
treatment because of its high reproducibility and potency, as well 
as the simple and accessible mode of application [9].
2 Materials
Use mouse strains sensitive to carcinogenesis induced by AOM 
(A/J, SWR/J, FVB/N, C57Bl/6J, BALB/c) provided by most 
commercial research animal manufacturers. Preferably, use male 
mice (see Note 1) of 8 weeks of age in all experiments. For animal 
experimentation, follow FELASA guidelines and approval of the 
corresponding Ethics Committee for Animal Experimentation.
Dissolve the content of the ampule in 10 mL of sterilized ultrapure 
water to make a stock solution of 2.5 mg/mL. Make aliquots and 
store at −20 °C.
2.1 Mouse Strains
2.2 Azoxymethane 
(AOM)(Sigma Aldrich)
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DSS from MP Biomedicals induces a severe colitis. The sulfur con-
tent is approximately 17% which corresponds to an average of 1.9 
sulfate groups per glucosyl residue of the dextran molecule (see 
Note 2).
 1. Animal facility water.
 2. Sodium chloride solution 0.9%.
 3. 1× HBBS (Sigma).
 4. EDTA 0.5 M (Lonza).
 5. DTT (Fisher Scientific).
 6. Percoll (Sigma).
 7. Collagenase D (Roche).
 8. Dispase II (Sigma).
 9. DNase (Resuspend at 10KU/mL) (Sigma).
 10. Fetal calf serum (FCS).
 11. Paraformaldehyde (PFA) 1%.
 12. Anti CD8a-FITC (Miltenyi Biotec).
 13. AntiF4/80-APC (Miltenyi Biotec).
 14. Anti CD11bFITC-FITC (Miltenyi Biotec).
 1. Professional adjustable-volume micropipet (1000 μL).
 2. Micropipette tips (1000 μL).
 3. Disposable Syringe 1 mL.
 4. Syringe needles gauge 25, L 1/2 in.
 5. Precision laboratory balance.
 6. Digital caliper.
 7. Scissors.
 8. Forceps.
 9. Petri dishes.
 10. Round-bottom plate (Nunc, Thermo Fisher Scientific).
 11. 40 and 100 μm cell strainers (Falcon; BD).
 12. 15 and 50 mL conical centrifuge tubes.
 13. Thermal incubator with rotation unit.
 14. Cell culture centrifuge.
 15. Orbital Shaker.
2.3 Dextran Sulfate 
Sodium Salt (DSS) 
Colitis Grade (MP 
Biomedicals)  
(see Note 2)
2.4 Additional 
Reagents
2.5 Equipment
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3 Methods
 1. Separate the cages with the 8-week-old male mice, which will be 
used in the experimental and control groups. Mice should be 
labeled individually with tail tags or ear punching. Two animal 
groups should be prepared: Control group (receiving isotonic 
solution and water) and CAC group (receiving AOM and DSS).
 2. Prepare a working solution of AOM from the stock solution at 
10 mg/mL stored at −20 °C. This working solution is dissolved 
in isotonic saline solution at a concentration of 1 mg/mL.
 3. Inoculate mice intraperitoneally (IP) with AOM working solution 
(1 mg/mL) at 10 mg/kg of weight. For the greatest precision in 
dosing, each animal should be weighed. The weights and doses 
must be recorded. Calculate injection volume by multiplying ani-
mal’s weight (kg) × dose (mg/kg) and divide this by the concen-
tration of working solution (mg/mL). The same volume of 
isotonic solution is inoculated in the control groups (see Note 3).
 4. Prepare 2.5% DSS solution. Add 100 mL of animal drinking 
water to a 1 L glass beaker. Weigh 25 g of DSS and transfer to 
the glass and mix until a clear solution is obtained. Add animal 
drinking water for a total volume of 1000 mL. Fill the animal 
water bottle with 100 mL of 2.5% DSS solution and place in 
the corresponding cages. Control mice should get only water. 
All mice have ad libitum access to drinking water containing 
2.5% DSS or water (control group) for 5 days (see Note 4).
 5. CAC is induced by intraperitoneal injection of a single dose of 
the mutagenic agent AOM (10 mg/kg) on day 0 followed by 
3 cycles of 2.5% DSS in drinking water for 5 days and normal 
drinking water for 2 weeks (Fig. 1).
3.1 Induction 
of Colitis-Associated 
Cancer (CAC)
Fig. 1 Protocol for DSS/AOM-induced colitis-associated cancer. Animals receive a single dose intraperitoneally 
of the mutagenic agent AOM (10 mg/kg) on day 0 followed by 3 cycles of 2.5% DSS in drinking water for 5 
days and normal drinking water for 2 weeks. Control mice only receive water
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 1. Mice should be weighted and observed daily. Clinical measure-
ments of the disease severity are conducted. The scoring sys-
tem uses five different parameters to calculate the severity of 
the disease: weight loss, stool consistency, visible fecal blood, 
mouse behavior, and dehydration (Table  1). All individual 
scores are added, resulting in a total clinical score with a 
 maximum of 24 per mouse (see Note 5). An example of disease 
monitoring employing this clinical score is shown in Fig. 2.
 1. On day 56, colorectal tumors can be treated with chemother-
apy or immunotherapy protocols. Dose and duration should 
be adjusted depending on the treatment (see Note 6).
 2. On day 56 (or after the corresponding day in case of experi-
mental therapy), euthanize animals in CO2 gas chamber or use 
any other method in accordance with approved protocol by 
Ethics Committee for Animal Experimentation.
 3. Sterilize with 70% ethanol solution and carefully make a ven-
tral midline incision in the skin to open the abdominal cavity. 
Expose the intestine until the cecum is visible. Separate the 
colon from the small intestine. At this step the difficulty to 
separate colon from small intestine should be evaluated to 
measure the degree of adhesion, a parameter of the macro-
scopic score (Table 2).
 4. Cut off the colon just above the cecum and at the end of the 
rectum.
 5. Measure and weight the colon (see Note 7).
 (a)  To measure the colon length use a rule or an electronic 
digital caliber. Put the organ straight but avoid stretching 
and prevent tissue breakage. Only the colon, excluding the 
cecum, should be measured.
3.2 Evaluation 
of Clinical Score
3.3 Evaluation 
of Macroscopic 
Damage in Colon 
and Tumor 
Development
Table 1 
Assessment of clinical score
Parameters and score
Weight changes (g) <1% = 0; 1–5% = 1; 5–10% = 2; 10–20% = 3; >20% = 4
Stool consistency Normal = 0; soft feces = 1; diarrhea = 4
Visible bleeding No visible = 0; visible bleeding = 4
Mouse behavior Normal = 0; slight changes = 1 abnormal = 4; immobility = 8
Dehydration Normal = 0; dehydration = 4
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 (b)  Separate the cecum and flush the colon to eliminate the 
feces with 5 mL of sterile PBS using a syringe with a 21G 
 needle or a micropipette tip (1000 μL). Weight the cleaned 
colon and score.
 6. Carefully open the colon longitudinally and wash again with 
sterile PBS.
 7. Observe and score the visible colonic damage. The scoring 
system assigns severity scores to six parameters: diarrhea, 
Fig. 2 Representative data of weight loss and clinical score. CAC was induced in male C57BL/6 wild-type (B6) 
mice following the DSS/AOM protocol. Change in weight was recorded and clinical score was established and 
evaluated every single day. Control group only received water during the experiment
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bleeding, erythema, edema, stenosis, and adhesions (Table 2). 
All individual scores are added, resulting in macroscopic 
 damage score. An example of colon length, colon weight, and 
macroscopic damage evaluation monitoring is shown in Fig. 3.
 8. Count the number of macroscopic tumors per mouse in the 
longitudinally open colon.
 9. Measure tumor diameter using a digital caliper. (An example 
of the tumor appearance is shown in Fig. 4).
 10. Calculate the percentage of tumor incidence.
Figure 5 shows the schematic diagram of the protocol to isolate 
colonic lymphoid cells (LPMCs and IELs).
 1. Prepare the predigestion solution by adding 5 mM EDTA and 
1  mM DTT to HBSS (1×) (100  μL of 0.5  M EDTA and 
100 μL of 0.1 M DTT for a total volume of 10 mL HBSS).
3.4 Isolation 
of Intraepithelial 
Lymphocytes (IELs) 
and Lamina Propria 
(LP) Leukocytes
Table 2 
Assessment of clinical score
Parameters and score
Diarrhea Normal = 0; soft = 1; liquid = 4
Bleeding No = 0; Yes = 4
Erythema No = 0; Mild and/or localized = 1; intense and/or generalized = 2
Edema No = 0; Mild and/or localized = 1; intense and/or generalized = 2
Stenosis No = 0; 1 Stenosis = 1; 2 Stenosis = 2; >2 Stenosis = 3
Adherencesa No adhesions = 0; Difficult dissection = 1; Visible adhesions = 2; 
¨Wrapped¨ intestine = 3
aEvaluate the adherences during dissection
Fig. 3 Representative data of colon length, colon weight, and macroscopic damage in colon. CAC was induced 
in male C57BL/6 wild-type (B6) mice following the DSS/AOM protocol. Animals were euthanized at day 56 and 
a macroscopic score was calculated as indicated in Table 2
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 2. After evaluating macroscopic damage and tumor development 
cut the colon into 1–2 cm pieces with the help of a scalpel or 
scissors. Place the small pieces in a 50 mL conical centrifuge 
tube prefilled with 5 mL of predigestion solution. Incubate for 
20 min at 37 °C under slow rotation in an orbital shaker. For a 
good cell yield, use at least three mice per experimental group.
Fig. 4 Representative picture of colon tumors from DSS/AOM-treated B6 wild- 
type mice at day 56. Tumors are counted macroscopically and diameter is deter-
mined using a digital caliper. CAC was induced in male C57BL/6 wild-type (B6) 
mice following the DSS/AOM protocol. Animals were euthanized at day 56
Fig. 5 Schematic summary of the protocol to isolate colonic lymphoid cells (LPMCs 
and IELs)
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 3. After incubation, filter the solution containing tissue rests and 
cells through a 100 μm cell strainer. Dissect the residual tissue 
layers using forceps.
 4. Reserve the flow-through that contains the dissected epithelial 
cells. Store at 4 °C for the isolation of IELs.
 5. Put the pieces retained at the top of the strainer into a 50 mL 
conical centrifuge tube prefilled with 5 mL of fresh prediges-
tion solution. Incubate for 20 min at 37 °C under slow rota-
tion in the orbital shaker.
 6. While tubes are shaking prepare Digestion solution: dissolve 
0.05 g of collagenase D, 0.05 g of DNase I, and 0.3 g of dis-
pase II in 100 mL of sterile 1× PBS. Prepare a fresh solution 
just before using and incubate for a few minutes at 37  °C 
(see Note 8).
 7. Filter the pieces through a 100 μm cell strainer. Using scissors 
cut the remaining tissue into 1  mm pieces. Collect the 
 flow- through into the 50 mL conical centrifuge tube reserved 
in step 4. Store at 4 °C for the isolation of IELs.
 8. Wash out the remaining EDTA from the tissue pieces by flush-
ing with sterile 1× PBS through the cell strainer. Collect the 
tissue into a 50 mL conical centrifuge tube containing 5 mL of 
digestion solution. Incubate the pieces at 37  °C for 20 min 
under slow rotation.
 1. For isolation of IELs, allow the cell suspension obtained in 
steps 4 and 7 to settle for 15 min at 20 °C. The pellet contains 
the crypts that can be used for the purification of IELs with 
Percoll gradient. Centrifuge cells at 500  ×  g for 10  min at 
20  °C.  Discard the supernatant and resuspend the pellet in 
cold sterile 1× PBS containing 5% of FCS.
 2. Centrifuge the cells at 500 × g for 10 min at 20 °C. Discard the 
supernatant and purify IELs performing a Percoll density gra-
dient (see Subheading 3.4.3).
 1. After incubation with digestion solution (step 8), vortex each 
tube containing cell suspension for 20  s. Pass the remaining 
pieces through a 40 μm cell strainer.
 2. Put together all the pieces into a 50 mL conical centrifuge tube 
prefilled with 5 mL of fresh digestion solution. Incubate the 
pieces at 37 °C for 20 min under slow rotation.
 3. Repeat steps 1 and 2 while connective tissue is visible on the 
strainer (normally 2 to 3 times is enough). The intestine should 
be now completely digested.
 4. Centrifuge the cell suspension at 500  ×  g for 10  min at 
20  °C.  Discard the supernatant and resuspend the pellet in 
cold sterile 1× PBS containing 5% of FCS.
3.4.1 IELs Isolation
3.4.2 LPMC Isolation
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 5. Centrifuge the cell suspension at 500  ×  g for 10  min at 
20 °C. Discard the supernatant and purify LPMCs performing 
a Percoll density gradient (see Subheading 3.4.3).
 1. Prepare 80% Percoll solution. Mix 8 mL of Percoll (density: 
1124 g/mL) separation solution with 2 mL of sterile 1× PBS.
 2. Prepare 40% Percoll solution. Mix 4 mL of Percoll (1124 g/mL 
of density) separation solution with 6 mL of sterile 1× PBS.
 3. Resuspend the pellet (obtained in Subheading 3.4.1, step 2 
and/or in Subheading 3.4.2, step 5) in 10 mL of 40% Percoll 
solution. Transfer to a 15 mL conical centrifuge tube.
 4. Using a Pasteur pipette carefully underlay 5 mL of 80% Percoll 
solution.
 5. Centrifuge the 40/80 Percoll gradient at 1000 × g for 20 min 
at 20 °C without brake. The LPMCs and IELs should be visi-
ble in a white ring at the interphase of the two different Percoll 
solutions. Erythrocytes should be visible in a red ring below 
the white ring. At the top is the layer of epithelial cells and at 
the bottom a pellet containing debris and dead cells.
 6. Using a pasteur pipette, aspirate most of the cells of the white 
ring without disturbing the interface. Add to 15 mL tube and 
wash once with 1× PBS.
 7. Centrifuge the cell suspension at 500  ×  g for 10  min at 
20  °C.  Discard the supernatant and resuspend the pellet in 
sterile 1× PBS containing 5% of FCS (see Note 9).
 1. Determine cell number. Adjust the concentration to 5 × 106 
cells/mL. Plate 5 × 105 cells (100 μL of cell suspension) into 
a 96-well round-bottom plate.
 2. Centrifuge at 500 × g for 5 min at 4 °C. Decant supernatant 
by inverting the plate.
 3. Resuspend cells in 50 μL of PBS supplemented with 5% fetal 
calf serum (PBS 5% FCS) containing rat anti-Mouse CD16/
CD32 mAb (Clone 2.4G2; Table 3) to prevent FcR unspecific 
binding.
 4. Resuspend cells in 100 μL of PBS supplemented with 5% fetal 
calf serum (PBS 5% FCS) containing the antibodies against the 
markers indicated in Table 3.
 5. Incubate for 10 min in the dark at 2–8 °C.
 6. Centrifuge at 500 × g for 5 min at 4 °C. Decant supernatant 
by inverting the plate.
 7. Wash cells with 200 μL of PBS 5% FCS.
 8. Centrifuge at 500 × g for 5 min at 4 °C. Decant supernatant 
by inverting the plate.
3.4.3 Percoll Density 
Gradient
3.5 Surface Protein 
Staining for Flow 
Cytometry
Llipsy Santiago et al.
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Table 3 
Examples of antibodies used for analysis of IELs and LPMC by flow 
cytometry
Cell type Antibodies Expected signal
CD8+ (ab) T Cells CD45, FITC (+)
CD8a, Alexa 405 (+)
TCRab, PE (+)
CD3, APC (+)
CD8+ (gd) T Cells CD45, FITC (+)
CD8a, Alexa 405 (+)
TCRgd, PE (+)
CD3, APC (+)
CD4+ T Cells CD45, FITC (+)
CD4, PE (+)
TCRab, PE (+)
CD3, APC (+)
Macrophages CD45, FITC (+)
CD11b, Alexa 405 (+)
CD11c, PE (+) (−)a
F4/80, APC (+)
Neutrophils CD45, FITC (+)
CD11b, Alexa 405 (+)
CD11c, PE (,)
Ly6G, APC (+)
NK cells CD45, FITC (+)
NKp46, Alexa 405 (+)
NK1.1, PE
CD49b, PE
(+)c
RORgt, APC (−)
DC CD45, FITC (+)
CD11b, Alexa 405 (+) (−)a
CD11c, PE (+)
F4/80, APC (−)
CD103, APC.Cy7 (+)
(continued)
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 9. Resuspend cells in 100 μL of 1% Paraformaldehyde (PFA) to 
fix the cells. Incubate for 1 h in the dark at 4 °C.
 10. Centrifuge at 500 × g for 5 min at 4 °C. Decant supernatant 
by inverting the plate.
 11. Resuspend cell pellet in a suitable amount of PBS for analysis 
by flow cytometry.
4 Notes
 1. Both males and females develop DSS/AOM colitis-associated 
cancer, but males develop more reproducible and aggressive 
disease than females.
 2. Dextran sulfate is a polyanionic derivative of dextran produced 
by esterification of Dextran with chlorosulfonic acid. The sul-
fur content is approximately 17% which corresponds to an 
average of 1.9 sulfate groups per glucosyl residue of the dex-
tran molecule. DSS from MP Biomedicals induces a severe 
colitis as indicated by different parameters including body 
weight loss, colon weight/length, Disease Activity Index, and 
histological scores. This DSS is well characterized and as indi-
cated by the manufacturer presents several advantages.
 (a) Highest sulfur content: 19%.
 (b) Highest chirality: +104° of specific rotation.
 (c) Lowest pH: 6.2 at 1% solution.
 3. Example of dosage calculation
 (a) Mouse: 30 g body weight (0.030 kg).
 (b) Required dose of AOM: 10 mg/kg.
 (c) Concentration of AOM working solution: 1 mg/mL.
Table 3
(continued)
Cell type Antibodies Expected signal
Eosinophils CD45, FITC (+)
CD11b, Alexa 405 (+)
Siglec-F, PE (+)
Ly6G, APC (+/−)b
Concentration of Ab used for the staining is indicated by the manufacturers. The fluo-
rophore is indicated as a reference and other similar dyes can be used
aBoth subsets (+ or −) have been described
bEosinophils express intermediate levels of Ly6G in colitic mice
cNK1.1 is only expressed in C57Bl/6 mouse strains
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 (d) Needed dose: 0.030 kg × 10 mg/kg = 0.30 mg.
 (e) Needed volume: 0.30 mg/1 mg/mL = 0.30 mL = 300 μL.
●	 Summarizing: A working solution at 1 mg/mL facili-
tates the dosage of the AOM.  In this way the mice’s 
body weight, in grams, multiplied per 10 is the volume 
to be administered, in μL.
 (f) Inoculated AOM volume (μL) = body weight (g) × 10.
 4. In generally, DSS is used in a range of dose between 1.5 and 
3%. The reproducible induction of colitis depends on many 
factors that may influence its inflammatory potential, like 
genetic background of the animals, age, gender, animal health 
conditions and the institutional animal facility environmental 
factors, as well as DSS characteristics (manufacturer, number 
of lots, sulfur content, molecular weight), concentration and 
treatment duration. Summarizing, it is necessary to determi-
nate the optimal DSS dose required. Normally, 120–150 mL 
of 2.5% DSS solution is enough for five mice and for a cycle 
(5 days) but is necessary to check DSS consumption in each 
group to ensure a correct treatment. While DSS is quite stable 
at room temperature, treatment should be changed if any 
growth (turbidity) appears.
 5. DSS administration induces clinical signs rapidly. These symp-
toms worsen dramatically, increasing clinical score and mortal-
ity, particularly in the first recovery phase (days 8–12). Mice 
show weight loss, diarrhea, rectal bleeding, and piloerection. 
In more serious cases, mice will exhibit hunched back, symp-
toms of dehydration, and reduced mobility.
 6. For example, immunotherapy employing antibodies or soluble 
receptors against inflammatory cytokines, like TNFα, have 
been shown to reduce the incidence of CAC in mice at a dose 
of 3 mg/kg [10].
 7. The length of the colon decreases as colitis develops, which is 
a quantitative measure of disease severity. At the same time, the 
colonic wet weight increases in chronic gut inflammation, 
being another parameter to quantify [11, 12].
 8. The amount of DNase I must be enough to digest DNA and 
avoid sample viscosity. If the cell suspension clumps together, 
increase the amount of DNase I [13].
 9. Purified LPMCs and IELs can be used in flow cytometry analy-
sis (extracellular markers, cytotoxic molecules, and cytokines), 
cultured to quantify cytokines in supernatants or used to ana-
lyze cytotoxicity against tumor cells. Furthermore, cells can be 
used for proliferation assays, isolation of mRNA to perform 
PCR or protein isolation for western blot or ELISA 
experiments.
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